-
Risankizumab, sold
under the
brand name Skyrizi, is a
humanized monoclonal antibody used for the
treatment of
plaque psoriasis,
psoriatic arthritis, and...
-
Norvir (ritonavir) Mavyret/Maviret (glecaprevir/pibrentasvir)
Skyrizi (
risankizumab)
Rinvoq (upadacitinib)
Revenue US$54.32
billion (2023)
Operating income...
- than guselkumab,
tildrakizumab or
risankizumab,
which are
inhibitors of the p19
subunit of IL-23. However,
risankizumab has been
shown to have the best...
-
Interleukin 23 (SGRF) Antibodies:
Brazikumab Briakinumab Guselkumab Risankizumab Tildrakizumab Ustekinumab IL-27 Agonists:
Interleukin 27 (interleukin...
- ustekinumab, the IL-17A
inhibitor secukinumab, and the IL-23
inhibitor risankizumab.
Biologics may
increase the risk of
minor and
serious infections. More...
-
Sarilumab L04AC15
Sirukumab L04AC16
Guselkumab L04AC17
Tildrakizumab L04AC18
Risankizumab L04AC19
Satralizumab L04AC20
Netakimab L04AC21
Bimekizumab L04AC22 Spesolimab...
- infliximab, adalimumab, certolizumab, vedolizumab, ustekinumab, natalizumab,
risankizumab-rzaa, and
upadacitinib Hydrocortisone should be used in
severe attacks...
-
Olokizumab Ozanimod Peficitinib Pegcetacoplan Ponesimod Ravulizumab Risankizumab Ritlecitinib Rozanolixizumab Sarilumab Satralizumab Siltuximab Siponimod...
-
strong evidence to
indicate that infliximab, bimekizumab, ixekizumab, and
risankizumab are the most
effective biologics for
treating moderate to
severe cases...
-
Interleukin 23 (SGRF) Antibodies:
Brazikumab Briakinumab Guselkumab Risankizumab Tildrakizumab Ustekinumab IL-27 Agonists:
Interleukin 27 (interleukin...
